Copyright © 2004 by the European Society of Cardiology.
Clinical research
The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm
a Internal Medicine, Section of Vascular Medicine, UMC Utrecht, Utrecht, The Netherlands
b Julius Centre for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands
c Department of Neurology, UMC Utrecht, Utrecht, The Netherlands
* Corresponding Author: J. K. Olijhoek, MD, Internal Medicine, Section of Vascular Medicine, UMC Utrecht, G02.402, Heidelberglaan 100; 3584 CX Utrecht, The Netherlands. Tel.: +31-30-2509111; Fax: +31-30-2518328
E-mail address: J.K.Olijhoek{at}azu.nl
Received 1 July 2003; revised 24 November 2003; accepted 4 December 2003
Abstract
Aims The metabolic syndrome is associated with an increased risk of cardiovascular disease in patients without a cardiovascular history. We investigated whether the metabolic syndrome is related to the extent of vascular damage in patients with various manifestations of vascular disease.
Methods and results The study population of this cross-sectional survey consisted of 502 patients recently diagnosed with coronary heart disease (CHD), 236 with stroke, 218 with peripheral arterial disease (PAD) and 89 with abdominal aortic aneurysm (AAA). Metabolic syndrome was diagnosed according to Adult Treatment Panel III criteria. Carotid Intima Media Thickness (IMT), Ankle Brachial Pressure Index (ABPI) and albuminuria were used as non-invasive markers of vascular damage and adjusted for age and sex if appropriate.
The prevalence of the metabolic syndrome in the study population was 45%. In PAD patients this was 57%; in CHD patients 40%, in stroke patients 43% and in AAA patients 45%. Patients with the metabolic syndrome had an increased mean IMT (0.98 vs 0.92mm, P-value <0.01), more often a decreased ABPI (14% vs 10%, P-value 0.06) and increased prevalence of albuminuria (20% vs 15%, P-value 0.03) compared to patients without this syndrome. An increase in the number of components of the metabolic syndrome was associated with an increase in mean IMT (P-value for trend <0.001), lower ABPI (P-value for trend <0.01) and higher prevalence albuminuria (P-value for trend <0.01).
Conclusion In patients with manifest vascular disease the presence of the metabolic syndrome is associated with advanced vascular damage.
Key Words: Metabolic Syndrome Atherosclerosis Coronary heart disease Stroke Peripheral arterial disease Abdominal aortic aneurysm
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Maksimovic, H. Vlajinac, D. Radak, J. Marinkovic, and J. Jorga Relationship Between Peripheral Arterial Disease and Metabolic Syndrome Angiology, October 1, 2009; 60(5): 546 - 553. [Abstract] [PDF] |
||||
![]() |
D. Conen, K. M. Rexrode, M. A. Creager, P. M Ridker, and A. D. Pradhan Metabolic Syndrome, Inflammation, and Risk of Symptomatic Peripheral Artery Disease in Women: A Prospective Study Circulation, September 22, 2009; 120(12): 1041 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Holewijn, M. den Heijer, D. W. Swinkels, A. F. H. Stalenhoef, and J. de Graaf The Metabolic Syndrome and Its Traits as Risk Factors for Subclinical Atherosclerosis J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2893 - 2899. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.C. Bennett, S. Silverman, P.S. Gill, and G.Y.H. Lip Ethnicity and peripheral artery disease QJM, January 1, 2009; 102(1): 3 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel The Metabolic Syndrome Endocr. Rev., December 1, 2008; 29(7): 777 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, J. B Lindsey, A. Khera, J. A. D. Lemos, C. R Ayers, A. Goyal, G. L Vega, S. A Murphy, S. M Grundy, and D. K Mcguire Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 96 - 101. [Abstract] [PDF] |
||||
![]() |
L. R. Qadan, A. A. Ahmed, H. A. Safar, M. A. Al-Bader, and A. A. Ali Prevalence of Metabolic Syndrome in Patients With Clinically Advanced Peripheral Vascular Disease Angiology, May 1, 2008; 59(2): 198 - 202. [Abstract] [PDF] |
||||
![]() |
A. M.J. Wassink, Y. van der Graaf, J. K. Olijhoek, F. L.J. Visseren, and for the SMART Study Group Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm Eur. Heart J., January 2, 2008; 29(2): 213 - 223. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M Zivkovic, J B. German, and A. J Sanyal Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease Am. J. Clinical Nutrition, August 1, 2007; 86(2): 285 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Arenillas, M. A. Moro, and A. Davalos The Metabolic Syndrome and Stroke: Potential Treatment Approaches Stroke, July 1, 2007; 38(7): 2196 - 2203. [Full Text] [PDF] |
||||
![]() |
G. R Hajer, Y. van der Graaf, J. K Olijhoek, M. C Verhaar, F. L J Visseren, and for the SMART Study Group Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome Heart, February 1, 2007; 93(2): 216 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Grundy Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1093 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kurl, J. A. Laukkanen, L. Niskanen, D. Laaksonen, J. Sivenius, K. Nyyssonen, and J. T. Salonen Metabolic Syndrome and the Risk of Stroke in Middle-Aged Men Stroke, March 1, 2006; 37(3): 806 - 811. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lahoz, I. Vicente, F. Laguna, M. F. Garcia-Iglesias, M. Taboada, and J. M. Mostaza Metabolic Syndrome and Asymptomatic Peripheral Artery Disease in Subjects Over 60 Years of Age Diabetes Care, January 1, 2006; 29(1): 148 - 150. [Full Text] [PDF] |
||||
![]() |
S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, October 25, 2005; 112(17): 2735 - 2752. [Full Text] [PDF] |
||||
![]() |
J. D. Knudson, U. D. Dincer, G. M. Dick, H. Shibata, R. Akahane, M. Saito, and J. D. Tune Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1038 - H1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Bushnell and D. Guzick Metabolic syndrome and intracranial atherosclerosis: A new link? Neurology, July 26, 2005; 65(2): 188 - 189. [Full Text] [PDF] |
||||
![]() |
C. A. Geluk, F. W. Asselbergs, H. L. Hillege, S. J.L. Bakker, P. E. de Jong, F. Zijlstra, and W. H. van Gilst Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial Eur. Heart J., July 1, 2005; 26(13): 1314 - 1320. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Milionis, E. Rizos, J. Goudevenos, K. Seferiadis, D. P. Mikhailidis, and M. S. Elisaf Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects Stroke, July 1, 2005; 36(7): 1372 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Koren-Morag, U. Goldbourt, and D. Tanne Relation Between the Metabolic Syndrome and Ischemic Stroke or Transient Ischemic Attack: A Prospective Cohort Study in Patients With Atherosclerotic Cardiovascular Disease Stroke, July 1, 2005; 36(7): 1366 - 1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zeller, P. G. Steg, J. Ravisy, Y. Laurent, L. Janin-Manificat, I. L'Huillier, J.-C. Beer, A. Oudot, G. Rioufol, H. Makki, et al. Prevalence and Impact of Metabolic Syndrome on Hospital Outcomes in Acute Myocardial Infarction Arch Intern Med, May 23, 2005; 165(10): 1192 - 1198. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. B. Garin, B. Kalix, A. Morabia, and R. W. James Small, Dense Lipoprotein Particles and Reduced Paraoxonase-1 in Patients with the Metabolic Syndrome J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2264 - 2269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Olijhoek, J.-D. Banga, P. A. Doevendans, and F. L.J. Visseren Oral glucose tolerance test or metabolic syndrome criteria to predict risk in patients with coronary heart disease? Eur. Heart J., March 2, 2005; 26(6): 623 - 623. [Full Text] [PDF] |
||||
![]() |
J. K. Olijhoek, J. Koerselman, P. P.Th. de Jaegere, M. C. Verhaar, D. E. Grobbee, Y. van der Graaf, F. L.J. Visseren, and for the SMART Study Group Presence of the Metabolic Syndrome Does Not Impair Coronary Collateral Vessel Formation in Patients With Documented Coronary Artery Disease Diabetes Care, March 1, 2005; 28(3): 683 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf Prevention and Treatment of the Metabolic Syndrome Angiology, November 1, 2004; 55(6): 589 - 612. [Abstract] [PDF] |
||||
![]() |
S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf Prevention and Treatment of the Metabolic Syndrome Angiology, November 1, 2004; 55(6): 589 - 612. [Abstract] [PDF] |
||||














